A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine PDS01ADC in Localized High and Intermediate Risk Prostate Cancer Treated With Androgen Deprivation Therapy

NCT05361798 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

65

Enrollment

NIH

Sponsor class

Conditions

Cancer Of Prostate

Interventions

DRUG: PDS01ADC
RADIATION: Stereotactic Body Radiation Therapy (SBRT)

Sponsor

National Cancer Institute (NCI)